MedTrace Logo

Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone

NCT06612697 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 262

Last updated 2024-09-25

No results posted yet for this study

Summary

Nasopharyngeal carcinoma (NPC) is a malignant tumor primarily originating in the nasopharynx, commonly found in populations in southern China, certain regions of Asia, and North Africa. The main treatment for NPC is primarily radiotherapy, with some patients receiving combined chemotherapy. Early-stage NPC patients can achieve adequate tumor control with radiation therapy alone. Various studies report that the 5-year survival rate for very early-stage NPC exceeds 90%. However, some stage I patients experience local recurrence or distant metastasis after treatment, indicating treatment failure. This study aims to retrospectively analyze the factors contributing to treatment failure and prognostic factors in this group of early-stage NPC patients.

Conditions

  • Nasopharyngeal Carcinoma (NPC)
  • Oncology
  • Radiology

Interventions

OTHER

Radiology

A retrospective analysis was conducted using systematic records from the Department of Radiation Oncology at our hospital. The study included patients diagnosed with nasopharyngeal carcinoma through endoscopic pathological reports from January 1, 1984, to December 31, 2022. Eligible patients had baseline imaging (CT or MRI) prior to treatment, received definitive radiotherapy at our institution, and were followed up long-term with complete medical records.

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-02
Primary Completion
2024-07-01
Completion
2025-09-01

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06612697 on ClinicalTrials.gov